Human melanoma metastasis in NSG mice correlates with clinical outcome in patients

Elsa Quintana, Elena Piskounova, Mark Shackleton, Daniel Weinberg, Ugur Eskiocak, Douglas R. Fullen, Timothy M. Johnson, Sean J. Morrison

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Studies of human cancer metastasis have been limited by a lack of experimental assays in which cancer cells from patients metastasize in vivo in a way that correlates with clinical outcome. This makes it impossible to study intrinsic differences in the metastatic properties of cancers from different patients. We recently developed an assay in which human melanomas readily engraft in nonobese diabetic/severe combined immunodeficient interleukin-2 receptor-γ chain null (NSG) mice. We show that melanomas from 25 patients exhibited reproducible differences in the rate of spontaneous metastasis after transplantation into NSG mice and that these differences correlated with clinical outcome in the patients. Stage IIIB/C melanomas that formed distant metastases within 22 months in patients also formed tumors that metastasized widely in NSG mice, whereas stage IIIB/C melanomas that did not form distant metastases within 22 to 50 months in patients metastasized more slowly in NSG mice. These differences in the efficiency of metastasis correlated with the presence of circulating melanoma cells in the blood of NSG mice, suggesting that the rate of entry into the blood is one factor that limits the rate of metastasis. The study of NSG mice can therefore yield information about the metastasis of human melanomas in vivo, in this case revealing intrinsic differences among stage III melanomas in their ability to circulate/survive in the blood and to metastasize.

Original languageEnglish (US)
Article number159ra149
JournalScience Translational Medicine
Volume4
Issue number159
DOIs
StatePublished - Nov 7 2012

Fingerprint

Melanoma
Neoplasm Metastasis
Neoplasms
Interleukin-2 Receptors
Blood Cells
Transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Quintana, E., Piskounova, E., Shackleton, M., Weinberg, D., Eskiocak, U., Fullen, D. R., ... Morrison, S. J. (2012). Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Science Translational Medicine, 4(159), [159ra149]. https://doi.org/10.1126/scitranslmed.3004599

Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. / Quintana, Elsa; Piskounova, Elena; Shackleton, Mark; Weinberg, Daniel; Eskiocak, Ugur; Fullen, Douglas R.; Johnson, Timothy M.; Morrison, Sean J.

In: Science Translational Medicine, Vol. 4, No. 159, 159ra149, 07.11.2012.

Research output: Contribution to journalArticle

Quintana, E, Piskounova, E, Shackleton, M, Weinberg, D, Eskiocak, U, Fullen, DR, Johnson, TM & Morrison, SJ 2012, 'Human melanoma metastasis in NSG mice correlates with clinical outcome in patients', Science Translational Medicine, vol. 4, no. 159, 159ra149. https://doi.org/10.1126/scitranslmed.3004599
Quintana E, Piskounova E, Shackleton M, Weinberg D, Eskiocak U, Fullen DR et al. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Science Translational Medicine. 2012 Nov 7;4(159). 159ra149. https://doi.org/10.1126/scitranslmed.3004599
Quintana, Elsa ; Piskounova, Elena ; Shackleton, Mark ; Weinberg, Daniel ; Eskiocak, Ugur ; Fullen, Douglas R. ; Johnson, Timothy M. ; Morrison, Sean J. / Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. In: Science Translational Medicine. 2012 ; Vol. 4, No. 159.
@article{8f0a972b9aa94b08b9b66b359bf7fe41,
title = "Human melanoma metastasis in NSG mice correlates with clinical outcome in patients",
abstract = "Studies of human cancer metastasis have been limited by a lack of experimental assays in which cancer cells from patients metastasize in vivo in a way that correlates with clinical outcome. This makes it impossible to study intrinsic differences in the metastatic properties of cancers from different patients. We recently developed an assay in which human melanomas readily engraft in nonobese diabetic/severe combined immunodeficient interleukin-2 receptor-γ chain null (NSG) mice. We show that melanomas from 25 patients exhibited reproducible differences in the rate of spontaneous metastasis after transplantation into NSG mice and that these differences correlated with clinical outcome in the patients. Stage IIIB/C melanomas that formed distant metastases within 22 months in patients also formed tumors that metastasized widely in NSG mice, whereas stage IIIB/C melanomas that did not form distant metastases within 22 to 50 months in patients metastasized more slowly in NSG mice. These differences in the efficiency of metastasis correlated with the presence of circulating melanoma cells in the blood of NSG mice, suggesting that the rate of entry into the blood is one factor that limits the rate of metastasis. The study of NSG mice can therefore yield information about the metastasis of human melanomas in vivo, in this case revealing intrinsic differences among stage III melanomas in their ability to circulate/survive in the blood and to metastasize.",
author = "Elsa Quintana and Elena Piskounova and Mark Shackleton and Daniel Weinberg and Ugur Eskiocak and Fullen, {Douglas R.} and Johnson, {Timothy M.} and Morrison, {Sean J.}",
year = "2012",
month = "11",
day = "7",
doi = "10.1126/scitranslmed.3004599",
language = "English (US)",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "159",

}

TY - JOUR

T1 - Human melanoma metastasis in NSG mice correlates with clinical outcome in patients

AU - Quintana, Elsa

AU - Piskounova, Elena

AU - Shackleton, Mark

AU - Weinberg, Daniel

AU - Eskiocak, Ugur

AU - Fullen, Douglas R.

AU - Johnson, Timothy M.

AU - Morrison, Sean J.

PY - 2012/11/7

Y1 - 2012/11/7

N2 - Studies of human cancer metastasis have been limited by a lack of experimental assays in which cancer cells from patients metastasize in vivo in a way that correlates with clinical outcome. This makes it impossible to study intrinsic differences in the metastatic properties of cancers from different patients. We recently developed an assay in which human melanomas readily engraft in nonobese diabetic/severe combined immunodeficient interleukin-2 receptor-γ chain null (NSG) mice. We show that melanomas from 25 patients exhibited reproducible differences in the rate of spontaneous metastasis after transplantation into NSG mice and that these differences correlated with clinical outcome in the patients. Stage IIIB/C melanomas that formed distant metastases within 22 months in patients also formed tumors that metastasized widely in NSG mice, whereas stage IIIB/C melanomas that did not form distant metastases within 22 to 50 months in patients metastasized more slowly in NSG mice. These differences in the efficiency of metastasis correlated with the presence of circulating melanoma cells in the blood of NSG mice, suggesting that the rate of entry into the blood is one factor that limits the rate of metastasis. The study of NSG mice can therefore yield information about the metastasis of human melanomas in vivo, in this case revealing intrinsic differences among stage III melanomas in their ability to circulate/survive in the blood and to metastasize.

AB - Studies of human cancer metastasis have been limited by a lack of experimental assays in which cancer cells from patients metastasize in vivo in a way that correlates with clinical outcome. This makes it impossible to study intrinsic differences in the metastatic properties of cancers from different patients. We recently developed an assay in which human melanomas readily engraft in nonobese diabetic/severe combined immunodeficient interleukin-2 receptor-γ chain null (NSG) mice. We show that melanomas from 25 patients exhibited reproducible differences in the rate of spontaneous metastasis after transplantation into NSG mice and that these differences correlated with clinical outcome in the patients. Stage IIIB/C melanomas that formed distant metastases within 22 months in patients also formed tumors that metastasized widely in NSG mice, whereas stage IIIB/C melanomas that did not form distant metastases within 22 to 50 months in patients metastasized more slowly in NSG mice. These differences in the efficiency of metastasis correlated with the presence of circulating melanoma cells in the blood of NSG mice, suggesting that the rate of entry into the blood is one factor that limits the rate of metastasis. The study of NSG mice can therefore yield information about the metastasis of human melanomas in vivo, in this case revealing intrinsic differences among stage III melanomas in their ability to circulate/survive in the blood and to metastasize.

UR - http://www.scopus.com/inward/record.url?scp=84869147424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869147424&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3004599

DO - 10.1126/scitranslmed.3004599

M3 - Article

C2 - 23136044

AN - SCOPUS:84869147424

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 159

M1 - 159ra149

ER -